HIGHLIGHTS
SUMMARY
High rates of morbidity and mortality among patients with TBM are due in part to delays in diagnosis and hence prompt initiation of anti-TB treatment, as well as poor CSF penetration of many anti-TB drugs such as rifampin. There are only limited data on the impact of drug-resistance on clinical outcomes among patients with TBM. The advent of sensitive molecular diagnostics such as Xpert MTB/ RIF, as well as implementation of new and repurposed drugs (i.e. bedaquiline, pretomanid, and linezolid) to treat MDR-TB present a tremendous opportunity to improve . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.